Sports & Exercise
In one study of 130 LQTS competitive athletes, only 1 had an LQTS-triggered event while playing.
Editorial: Toward a Long and Happy Life of a Patient With Genetic Heart Disease
Shared Decision: New Guidelines for Athletes – 2021
From Toward a Long and Happy Life of a Patient With Genetic Heart Disease– Etheridge and Saarel editorial on Return to Play:
These data reassure us that optimally treated athletes with a comprehensive “return-to-play” plan can compete with a low rate of adverse events.”
“Patients live long lives despite their genetic arrhythmia diagnoses. Data like those provided by Tobert et al. help us understand that once evaluated, appropriately monitored, and treated, most can return to play and hopefully live long and happy lives.”
Return to Play
In 1,287 athlete-years of follow-up, 15 athletes with LQTS had at least 1 nonlethal breakthrough cardiac event (BCE), translating to an RTP-BCE rate of 1.16 per 100 athlete-years.
Athletes with LQTS can safely RTP with a low risk of BCEs, after:
1) completing a comprehensive evaluation with risk stratification;
2) establishing a LQTS genotype- and phenotype – tailored treatment program; and
3) implementing a proper athlete- specific RTP plan.